Now showing items 1-3 of 3

    • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. 

      Eggermont, AMM; Blank, CU; Mandala, M; Long, GV; Atkinson, V; Dalle, S; Haydon, A; Lichinitser, M; Khattak, A; Carlino, MS; Sandhu, S; Larkin, J; Puig, S; Ascierto, PA; Rutkowski, P; Schadendorf, D; Koornstra, R; Hernandez-Aya, L; Maio, M; van den Eertwegh, AJM; Grob, J-J; Gutzmer, R; Jamal, R; Lorigan, P; Ibrahim, N; Marreaud, S; van Akkooi, ACJ; Suciu, S; Robert, C
      BACKGROUND:The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate ...
    • Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. 

      de Wit, R; de Bono, J; Sternberg, CN; Fizazi, K; Tombal, B; Wülfing, C; Kramer, G; Eymard, J-C; Bamias, A; Carles, J; Iacovelli, R; Melichar, B; Sverrisdóttir, Á; Theodore, C; Feyerabend, S; Helissey, C; Ozatilgan, A; Geffriaud-Ricouard, C; Castellano, D; CARD Investigators (2019-12)
      <h4>Background</h4>The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were ...
    • Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience. 

      Kingston, B; Kayhanian, H; Brooks, C; Cox, N; Chaabouni, N; Redana, S; Kalaitzaki, E; Smith, I; O'Brien, M; Johnston, S; Parton, M; Noble, J; Stanway, S; Ring, A; Turner, N; Okines, A (2017-12)
      <h4>Purpose</h4>Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prognosis is poor, and although radiotherapy (RT), systemic and intra-thecal (IT) chemotherapy are accepted treatment ...